ArticlePathogens (Basel, Switzerland)2025
Epidemiology of Respiratory Adenovirus Infections Among Hospitalized Children in Hainan Province, China, 2021-2024.
Article in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Risk factors for hospitalization in pediatric patients with human adenovirus infection and changes in epidemiological and clinical characteristics before and after the COVID-19 pandemic in China: a multicenter retrospective study.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Human adenoviruses (HAdVs) are significant viral pathogens associated with a wide spectrum of diseases, particularly acute respiratory tract infections (ARTIs) in children. This study aimed to characterize the epidemiological features of HAdV infections among hospitalized pediatric patients in Hainan Province, China, from January 2021 to December 2024, encompassing the COVID-19 pandemic and post-policy transition period. Among 31,843 hospitalized children with ARTIs, HAdVs were detected in 2464 cases (7.74%). Annual positivity rates were 4.87% in 2021, 7.21% in 2022, and 4.39% in 2023, and sharply increased to 11.58% in 2024. No significant sex-based difference in infection rates was observed. Distinctly seasonal and temporal patterns were noted, with a pronounced summer peak in 2024 and increased circulation throughout the year. A notable shift in dominant genotypes was observed, with HAdV-C initially prevailing, followed by a surge in HAdV-B between late 2023 and mid-2024. Children aged 1-7 years exhibited the highest positivity rates, indicating age-related susceptibility. Furthermore, co-infections were common and became increasingly predominant after the implementation of tNGS diagnostics, accounting for over 85% of HAdV-positive cases by 2023-2024. These findings suggest a post-pandemic resurgence of HAdV activity, shaped by altered population immunity, resumed social contact, and improved diagnostic sensitivity. Continuous molecular and epidemiological surveillance is essential to guide targeted interventions and inform pediatric respiratory infection management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.